GlassScriptPhysician profile
Kari D Deboo
NPI 1780963538
$2,378.94
in general payments reported to CMS, 2019-2025
22 companies · $914 in 2025
The $914 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $111 · 2022: $295 · 2023: $342 · 2024: $718 · 2025: $914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,873 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,873.35 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $730.90 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $299.67 | 2021-2025 | Entyvio, Hyqvia, Eohilia |
| Janssen Biotech, INC. | $266.09 | 2024-2025 | Stelara, Tremfya |
| Pfizer INC. | $162.88 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $151.98 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $105.35 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $82.23 | 2025 | Rezdiffra |
| Ipsen Biopharmaceuticals, INC | $72.54 | 2024-2025 | Iqirvo, Bylvay |
| Lilly USA, LLC | $67.50 | 2024-2025 | Omvoh |
| Braintree Laboratories, INC. | $57.51 | 2021-2024 | Sutab, Suflave |
| Celgene Corporation | $55.00 | 2023-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $53.58 | 2025 | Vowst |
| Merck Sharp & Dohme LLC | $47.35 | 2023-2024 | Dificid, Zinplava |
| Orphalan INC | $45.73 | 2025 | Cuvrior |
| Genzyme Corporation | $35.07 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $31.54 | 2025 | Vegzelma |
| Tersera Therapeutics LLC | $29.63 | 2025 | Xermelo |
| Gilead Sciences, INC. | $19.44 | 2022 | |
| Glaxosmithkline, LLC. | $17.79 | 2021 | |
| Intercept Pharmaceuticals, INC. | $17.52 | 2022 | |
| Enterra Medical, INC. | $15.38 | 2022 | |
| Fresenius Kabi USA, LLC | $14.26 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kari Deboo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.